Healthcare Services

A Significant Growth Driver for the Febrile Neutropenia Market Is the Rising Cancer Prevalence Fueling Growth In The Market

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Febrile Neutropenia Market In 2026 And What Value Is Projected For 2030?

The febrile neutropenia market size has demonstrated significant expansion in recent years. This market is anticipated to climb from $11.28 billion in 2025 to $11.99 billion by 2026, at a compound annual growth rate (CAGR) of 6.3%. The historical development of this market can be attributed to an increase in cancer chemotherapy usage, a rise in hospital admissions, the accessibility of broad-spectrum antibiotics, enhanced infection awareness, and the growth in oncology centers.

The febrile neutropenia market is poised for substantial expansion in the coming years, with projections indicating it will reach $15.19 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.1%. This anticipated growth is linked to factors such as advancements in targeted antimicrobial therapy, an expanding oncology patient population, enhanced early infection detection, increasing utilization of G-CSFs, and the broader application of precision oncology care. Noteworthy trends throughout this forecast period include the increasing occurrence of chemotherapy-induced neutropenia, a rise in the use of empirical antibiotic therapy, growing acceptance of supportive care treatments, the expansion of hospital-based infection management strategies, and improvements in diagnostic and monitoring technologies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Febrile Neutropenia Market?

The growing occurrence of cancer is anticipated to fuel the expansion of the febrile neutropenia market moving forward. Cancer refers to a diverse collection of diseases identified by the uncontrolled proliferation of abnormal cells that can infiltrate nearby tissues and spread to other areas of the body. The rising number of cancer cases is influenced by factors such as an aging population, environmental and occupational exposures, genetic predispositions, and hormonal and reproductive elements. Febrile neutropenia assists cancer patients by emphasizing the elevated risk of infections during chemotherapy, which encourages swift intervention and targeted therapies to avert severe complications, thereby enhancing patient outcomes and allowing for continuous cancer treatment. For instance, in 2024, the Canadian Cancer Society, a Canada-based national cancer charity, reported that 32,100 people in Canada were diagnosed with lung cancer, accounting for 23.5% of all cancer-related deaths. Notably, lung cancer cases among females saw an increase from 15,800 cases in 2023 to 17,300 cases in 2024. As a result, the increasing prevalence of cancer is acting as a primary driver for the growth of the febrile neutropenia market.

What Are The Key Segments Of The Febrile Neutropenia Market?

The febrile neutropenia market covered in this report is segmented –

1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care

2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders

3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections

4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration

Subsegments:

1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems

2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy

3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management

What Key Trends Are Influencing The Development Of The Febrile Neutropenia Market?

Leading firms within the febrile neutropenia market are prioritizing the creation of sophisticated biosimilar medications, including extended-duration granulocyte-colony stimulating factor (G-CSF) fusion proteins, aiming to secure a competitive edge. Such fusion G-CSFs constitute recombinant proteins that couple G-CSF with an Fc fragment, thereby facilitating prolonged neutrophil stimulation throughout a chemotherapy cycle. An example occurred in November 2024 when Evive Biotech, a biopharmaceutical entity based in Singapore, launched in Germany a long-acting, non-pegylated G-CSF specifically for chemotherapy-induced neutropenia. This product achieves an extended half-life through an IgG2-Fc fusion and utilizes mammalian cell expression to ensure human-like glycosylation. These advanced and biosimilar G-CSFs enhance patient accessibility and lessen the frequency of dosing, despite encountering intricate regulatory hurdles and potential issues related to immunogenicity.

Who Are The Leading Companies Operating In The Febrile Neutropenia Market?

Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Hospira Inc., Coherus BioSciences Inc., Gennova Biopharmaceuticals Limited, Dr Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Bayer AG, Cipla Ltd., Zydus Cadila, Celltrion Inc., Samsung Bioepis Co. Ltd.

Read the full febrile neutropenia market report here:

https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

What Are The Leading Geographic Regions In The Febrile Neutropenia Market?

North America was the largest region in the febrile neutropenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Febrile Neutropenia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21187&type=smp

Browse Through More Reports Similar to the Global Febrile Neutropenia Market 2026, By The Business Research Company

Gauchers Disease Global Market Report

https://www.thebusinessresearchcompany.com/report/gauchers-disease-global-market-report

Lenalidomide Global Market Report

https://www.thebusinessresearchcompany.com/report/lenalidomide-global-market-report

Cephalosporin Global Market Report

https://www.thebusinessresearchcompany.com/report/cephalosporin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795